News Articles

Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology &... MONTREAL -Thursday, September 28th 2017 [ar]

(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its REP 301 study on the activity of REP 2139 and...

Replicor discloses achievement of 1 year functional control of HBV and HDV with NAPs and new mechanistic insights in NAP... MONTREAL -Thursday, April 20th 2017 [ar] [fr]

(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic HBV and HDV infection, today disclosed significant new data on NAP activity in HBV and HDV infections at the European Association for the Study of the Liver (EASL) 2017 annual meeting held...

Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016 NEW YORK -Tuesday, October 4th 2016 [ar] [fr]

(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver...

Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and... NEW YORK. -Tuesday, February 16th 2016 [ar] [fr]  

(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and updated clinical data on REP 2139-Ca based combination...